Abstract:BACKGROUND: Obesity is a metabolic disorder that becomes epidemic. Visceral adiposity increases the risk of arterial hypertension, diabetes mellitus and other comorbidities. According to this, the main aim of obesity treatment is not only a weight loss but also a decrease of the risk of comorbidities. AIMS: to assess the efficiency and safety of sibutramine in patients with obesity and arterial hypertension, to evaluate the drug influence on epicardial fat thickness. MATERIALS AND METHODS: 57 patients aged 35-60 with obesity and arterial hypertension were included in the study. All patients at the beginning and after 7 months of follow-up underwent complex examination including anthropometric measurement, ECG, office and ambulatory blood pressure measurement, echocardiography. Patients with controlled arterial hypertension were included. During the first month of follow-up patients were given general weight loss recommendations. Then sibutramine was added. Control visits to assess efficiency and safety of drug treatment were held after 1 and 6 months of follow-up. RESULTS: Women predominated among the study participants. Visceral adiposity was approved by anthropometric measurements among all patients. Most patients had impaired left ventricle geometry: concentric remodeling or hypertrophy. During the first month of follow-up the weight loss was mild: 2 kg (less than 2%) in average. Sibutramine for 1 month the weight loss increased: 3.7 kg (more than 2%) in average. After 6 months of drug administration the weight loss of patients consisted 8.6 kg (6.2%) in average. According to echocardiography results indexed mass of LV myocardium decreased in all patients more significantly in women. Also in this group of patients significant decrease of epicardial fat thickness was revealed. Adverse events of sibutramine were revealed in 26.3% of patients. The most frequent were constipation (12.3%) and dry mouth (10.6%). The severity of symptoms persisted for 1 month and then decreased, additional therapy was not required. CONCLUSIONS: Sibutramine treatment of obesity promotes effective weight loss, influences the adipose tissue distribution, decreases the progress of associated comorbidities. Sibutramine is an effective and safe drug that can be used in patients with visceral adiposity and controlled arterial hypertension.

Body Mass Change in Overweight and Simple Obesity Patients 1 Year after Withdrawal of Sibutramine

Efficacy and Safety of Sibutramine in Chinese Obese Patients

Level of Free Fat Acid Could Be Decreased in Obese Subjects after 6 Months' Treatment with Sibutramine

Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial

Effect of Meal Replacements on Body Weight Control and Blood Glucose and Lipid Profile

The Effect of Sibutramine on Plasm Leptin and Insulin Levels in Obesity

1672-P: Weight Changes after Tirzepatide Cessation in Chinese Adults with Overweight/Obesity—A Real-World Follow-up Study of SURMOUNT-CN Trial

The experience of sibutramine administration in patients with obesity and controlled arterial hypertension

[Patients with type III obesity given sibutramine 15 mg/day lose weight in amounts proportional to those in types I and II, but waist circumferences does not decrease proportionally]

EFFICACY OF SIBUTRAMINE AND TOPIRAMATE COMBINATION IN WEIGHT LOSS: RETROSPECTIVE COHORT STUDY ON BRAZILIAN ADULTS

Comparison of Weight Loss Induced by Dietary and Pharmaceuticals in Individuals with Overweight and Obesity: A Retrospective Study

Clinical Efficacy of Orlistat in Chinese Overweight and Obese Patients with Newly Diagnosed Type 2 Diabetes

The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials

Natural Course of Metabolically Healthy Overweight/Obese Subjects and the Impact of Weight Change.

Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success

Chinese Herbal Medicine for Obesity: A Randomized, Double-Blinded, Multicenter, Prospective Trial

Natural Course of Metabolically Healthy Overweight/Obese Subjects and the Impact of Weight Change

36-Month Evaluation of a Weight Management Programme in Chinese Overweight and Obese Adults

Comparison of the exercise pressor reflex between forelimb and hindlimb muscles in cats.

Mobile-Based Platform With a Low-Calorie Dietary Intervention Involving Prepackaged Food for Weight Loss for People With Overweight and Obesity in China: Half-Year Follow-Up Results of a Randomized Controlled Trial

Efficacy and Safety of a Chinese Herbal Medicine Formula (RCM-104) in the Management of Simple Obesity: A Randomized, Placebo-Controlled Clinical Trial